Lifecore Biomedical, Inc.
LFCR
$6.38
$0.213.40%
NASDAQ
| 02/23/2025 | 11/24/2024 | 08/25/2024 | 05/26/2024 | 02/25/2024 | |
|---|---|---|---|---|---|
| Net Income | -124.76% | 59.51% | -129.14% | -145.31% | 9.95% |
| Total Depreciation and Amortization | 1.57% | 2.56% | 13.76% | -12.66% | 13.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 129.62% | 16.09% | -31.30% | 162.27% | 7.50% |
| Change in Net Operating Assets | 71.94% | -216.46% | 64.04% | 196.20% | -698.99% |
| Cash from Operations | 119.64% | -850.23% | -107.44% | 709.31% | -210.09% |
| Capital Expenditure | -120.89% | 27.18% | -28.63% | 58.58% | -49.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 162.51% | 27.18% | -28.63% | 58.58% | -49.43% |
| Total Debt Issued | -- | -200.00% | -98.69% | 4,726.43% | 237.21% |
| Total Debt Repaid | 45.47% | -4,803.86% | 99.84% | -63,234.48% | -3.57% |
| Issuance of Common Stock | -99.93% | 2,383,900.00% | -- | -- | -- |
| Repurchase of Common Stock | 65.45% | 34.63% | -1,011.32% | -26.19% | -250.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -118.13% | -- | -- | -102.19% | -- |
| Cash from Financing | -154.19% | 1,045.01% | 278.01% | -108.04% | 411.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -202.62% | 233.75% | -154.59% | 3,741.22% | 97.27% |